Business and science: How risky is SynBio?

Business and science: How risky is SynBio?

Up next

The birth of India's call centre industry

In 1997, after years working abroad, Pramod Bhasin returned to India and spotted an opportunity that would help transform his country's economy.Despite major telecommunications challenges, he went on to set up India's first call centre, laying the foundations for a new outsourcin ...  Show more

Headspace: from mindfulness app to military partner

Headspace started life as a mindfulness app. Now it's partnering with the US Navy and investing in artificial intelligence for mental health support.The company's CEO Tom Pickett speaks to us about therapy, the increasing role of technology, and tackling burnout at scale.If you'd ...  Show more

Recommended Episodes

Turning Cells into Tiny Factories
What's Your Problem?

Reshma Shetty is co-founder and chief operations officer of Ginkgo Bioworks. Her problem: How do you turn cutting-edge science into a sustainable business?

Ginkgo is a synthetic biology company. The idea is to make industrial products -- fragrances, or food, or whatever ...

  Show more

Genetic dreams, genetic nightmares
Discovery

Professor Matthew Cobb looks at how genetic engineering became big business - from the first biotech company that produced human insulin in modified bacteria in the late 1970s to the companies like Monsanto which developed and then commercialised the first GM crops in the 1990s. ...  Show more

Making money in biotech stocks
Investing Experts

How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10).Show Notes:Finding Winners In Biotech, Probably The Riskiest SectorSyn ...  Show more

Why We’re In a ‘Golden Age’ of Life Sciences Innovation
Exchanges

The business of life sciences came into sharp focus after the pandemic highlighted the effectiveness of mRNA vaccines in protecting people against COVID. But what exactly is life sciences and is the recent market weakness a threat to future innovation — or an opportunity? In the ...  Show more